Sight Sciences, Inc. (SGHT) Market Cap
Sight Sciences, Inc. has a market capitalization of $220.9M.
Financials based on reported quarter end 2025-12-31
Price: $4.09
▲ 0.26 (6.79%)
Market Cap: 220.88M
NASDAQ · time unavailable
CEO: Paul Badawi
Sector: Healthcare
Industry: Medical - Devices
IPO Date: 2021-07-15
Website: https://www.sightsciences.com
Sight Sciences, Inc. (SGHT) - Company Information
Market Cap: 220.88M · Sector: Healthcare
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Analyst Sentiment
Based on 6 ratings
Analyst 1Y Forecast: $8.63
Average target (based on 3 sources)
Consensus Price Target
Low
$8
Median
$9
High
$12
Average
$10
Potential Upside: 136.4%
Price & Moving Averages
Related Companies in Healthcare
ANTERIS TECHNOLOGIES GLOBAL CORP (AVR)
Healthcare
$0.22B
Mkt Cap
ORASURE TECHNOLOGIES INC (OSUR)
Healthcare
$0.22B
Mkt Cap
AVIDITY BIOSCIENCES INC (RNA)
Healthcare
$0.22B
Mkt Cap
ELECTROMED INC (ELMD)
Healthcare
$0.22B
Mkt Cap
NEOGENOMICS INC (NEO)
Healthcare
$0.22B
Mkt Cap
UTAH MEDICAL PRODUCTS INC (UTMD)
Healthcare
$0.23B
Mkt Cap
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"SGHT reported revenue of $20.39M for the fiscal year ended December 2025, translating to a notable growth trajectory despite a net loss of $4.16M. The company's earnings per share stands at -$0.0784, reflecting ongoing challenges in profitability. Cash flow concerns are evident as the operating cash flow is negative at -$1.83M, alongside a free cash flow of -$1.67M, indicating that the company is currently in a cash-burning phase. On the balance sheet, total assets amount to $115.3M against total liabilities of $51.36M, leading to a favorable net debt position of -$51.67M, showcasing ample assets over liabilities. Despite the negative cash flows and net income, SGHT has experienced a strong 1-year price appreciation of 25.41%, signaling positive market sentiment towards its growth potential. The current share price is $3.85, with a consensus target price of $9.67 suggesting substantial upside, albeit not without risk given its capital structure and operational losses."
Revenue Growth
Revenue of $20.39M showcases strong growth.
Profitability
Net loss indicates ongoing profitability challenges.
Cash Flow Quality
Negative operating and free cash flow raise concerns.
Leverage & Balance Sheet
Strong asset position with manageable liabilities.
Shareholder Returns
Positive price appreciation of 25.41% reflects some return.
Analyst Sentiment & Valuation
Target price suggests potential upside, though risk remains.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Management delivered a confident, execution-focused story: TearCare reached a core reimbursement inflection (CPT 0563T pricing set by Novitas and First Coast in Q4), and 2026 guidance ramps Interventional Dry Eye from $1.6M (prior year) to $5M-$7M while returning Interventional Glaucoma to modest growth (low-to-mid single digits market growth cited). However, the Q&A pressures the narrative: Dry eye upside is constrained primarily by commercial infrastructure—management explicitly said guidance does not assume additional MAC wins—and they declined to quantify peak TearCare sales. Near-term visibility is also softened by macro disruption (Jan/Feb storms) and by reimbursement/codec uncertainty (goniotomy revaluation risk in Jan 2028, expected adult adult code reduction). So while the tone is optimistic on reimbursement milestones and long-run TAM, analysts repeatedly probed for timing, magnitude, and sustainability—and management steered toward prudence and controllable constraints rather than aggressive forecasting.
Growth Catalysts
- Reimbursed Interventional Dry Eye launch milestone: MAC fee schedules established for CPT code 0563T (TearCare)
- Continued OMNI momentum in a post-LCD-change environment (fully lapped 2025 LCD restrictions in Q4 2025)
- Higher OMNI Edge utilization driving higher average selling prices (ASPs) in Q4
Business Development
- MAC pricing established in Q4 for CPT code 0563T by: Novitas Solutions and First Coast Service Options (2 MACs)
- TearCare commercial traction: ~700 SmartLids sold to ~80 accounts in Q4, including ~30 new account engagements
- Dry eye customer mix includes existing glaucoma customers expanding on TearCare opportunity
Financial Highlights
- Q4 total revenue: $20.4M (+7% YoY)
- Interventional Glaucoma Q4 revenue: $19.7M (+5% YoY, flat sequentially); ordering accounts +2% YoY
- Interventional Dry Eye Q4 revenue: $0.7M (vs $0.3M prior year)
- Interventional Dry Eye volume proxy: ~700 SmartLids to ~80 accounts; ~30 new accounts
- Gross margin: 87% (flat YoY); Interventional Glaucoma gross margin 88% (vs 87%), increase driven by higher ASP and product mix, slightly offset by tariff costs
- Interventional Dry Eye gross margin: 68% (vs 51%), driven by higher ASP/product mix
- Operating expense discipline: total operating expenses $21.5M (-25% YoY) and adjusted operating expenses $18.9M (-23% YoY) after August 2025 reduction in force
- Net loss: $4.2M or $0.08/share (vs net loss $11.8M or $0.23/share)
- Cash usage: $0.4M in Q4 (lowest cash usage quarter of the year); cash balance at quarter end: $92M (down from $120.4M end-2024)
- 2026 revenue guidance: $82M-$88M (+6% to +14% vs 2025); segment mix: Interventional Glaucoma $77M-$81M (+2% to +7%), Interventional Dry Eye $5M-$7M (vs $1.6M prior year)
- 2026 operating expense guidance: adjusted OpEx $93M-$96M (+6% to +9% vs 2025) driven by targeted market access and commercial investments
- Q1 2026: Interventional Glaucoma expected low single-digit YoY; Q1 expected to be lowest quarter in that segment; Interventional Dry Eye expected ~$1M in Q1
Capital Funding
- Cash and equivalents end of Q4: $92M
- Debt: $40M (excluding unamortized discount and debt issuance costs from 2024 year-end balance)
- Management stated intent to reach cash flow breakeven over time without raising additional equity capital
Strategy & Ops
- TearCare commercialization scaling: continued execution post MAC fee schedule milestone; investments in Interventional Dry Eye commercial organization
- Interventional Dry Eye: expanding provider engagement and market access outreach in newly reimbursed fee-schedule states; additional resources added in Q4 with continued build into 2026
- Interventional Glaucoma: investing in pseudophakic/stand-alone market development (about “half a dozen” dedicated market-development professionals stated in Q&A)
- 2026 spend focus: bulk of incremental investment in commercial infrastructure (dry eye market access + commercial build) while maintaining OpEx discipline
Market Outlook
- Full-year 2026 revenue guidance: $82M-$88M; Interventional Glaucoma $77M-$81M; Interventional Dry Eye $5M-$7M
- Full-year 2026 adjusted operating expense guidance: $93M-$96M
- Q1 2026 Interventional Glaucoma growth: low single digits YoY; Q1 expected to be lowest quarter for that segment
- Q1 2026 Interventional Dry Eye revenue: approximately $1M
- Management expectation: more MACs establishing fee schedules “this year,” but timing not specified
Risks & Headwinds
- Tariff costs: cited as a slight headwind to Interventional Glaucoma gross margin improvement (88% vs 87%)
- LCD headwinds fully lapped in Q4: 2025 LCD restrictions on multiple mix procedures with cataract surgery caused “meaningful headwinds” to market growth in 2025 (now lapped)
- Near-term volume/seasonality: storms across the U.S. in January and February cited as impacting Q1 2026 outlook
- Dry eye commercialization constraint: guidance described as prudent because the primary constraint is commercial infrastructure/resources (small team growing) rather than demand
- Guidance assumptions: Interventional Dry Eye 2026 guidance did not assume additional market access wins (management highlighted it is “baked in” prudently and assumes no additional MAC wins yet)
- Standalone glaucoma ramp time: requires building stand-alone case activation beyond education; described as taking time to develop significant markets
- Reimbursement risk (procedure economics): AMA elected new goniotomy code path effective Jan 2028; adult goniotomy is expected by “experts” to be reduced upon revaluation, which could pressure utilization (potential tailwind: OMNI may benefit if goniotomy economics tighten for stand-alone goniotomy)
Sentiment: MIXED
Note: This summary was synthesized by AI from the SGHT Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.